Celine Houser

Celine Houser's Title

Celine Houser holds the esteemed position of Vice President, Clinical Operations. Her role involves overseeing the clinical research and development processes, ensuring that clinical trials are executed efficiently and effectively. With her extensive experience and expertise, she plays a crucial role in strategic planning and operational execution of clinical programs.

Celine Houser's Education and Expertise

Celine Houser is a Registered Nurse by training, bringing a solid foundation in healthcare to her leadership role in clinical operations. With over 20 years of experience in clinical research, she has developed a deep understanding of the complexities involved in clinical trials, particularly in the field of neuropsychology. Her scientific interests include the placebo/nocebo response and functional unblinding, areas in which she has contributed significant insights.

Celine Houser's Background

Based in Toronto, Canada, Celine Houser balances a demanding professional life with being a mother to four incredible adults. Her passion for clinical research is matched by her dedication to her family. In her spare time, she enjoys the strategic challenge of playing chess. This balance of professional excellence and personal fulfillment highlights her multifaceted character.

Celine Houser's Achievements

Celine Houser has participated in over 100 neuropsych studies, demonstrating her extensive experience and commitment to advancing clinical research. She previously led Cognition Therapeutics’ clinical programs as Vice President of Clinical Operations, where she significantly contributed to the company's success. Her work focuses on improving outcomes for individuals with neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Schizophrenia, reflecting her passion for making a meaningful impact in the field.

Celine Houser's Company

Celine Houser has been associated with several organizations, both small and large, throughout her career in clinical research. At Cognition Therapeutics, she played a pivotal role in steering the company’s clinical programs. Her leadership and operational expertise have been instrumental in advancing the company's mission to develop innovative treatments for neurodegenerative diseases.